ArticleJCO global oncology2026
Chemotherapy Medications in Sub-Saharan Africa: Availability, Pricing, Affordability, and Predictors of Quality.
Article in JCO global oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
purposeWe assessed the availability, price, and affordability of commonly used chemotherapy medications in Cameroon, Ethiopia, Kenya, and Malawi. We also examined the characteristics that could predict chemotherapy medication quality.
methodsSamples of seven commonly used chemotherapy medications were collected: cisplatin, cyclophosphamide, doxorubicin, ifosfamide, leucovorin, methotrexate, and oxaliplatin. Stockouts and medicine prices were recorded at public national hospitals and community pharmacies. Using the National Comprehensive Cancer Network's harmonized guidelines for sub-Saharan Africa, we estimated the costs of medications to treat early-stage breast cancer, colorectal cancer (CRC), and head and neck cancer. Every sample was tested for quality using high-performance liquid chromatography against USP standards. We ran logistic regressions to assess medicine characteristics that could predict substandard and falsified chemotherapy medications.
resultsStockouts of chemotherapy medications in public hospitals were observed in three of four countries. Other than in Malawi where medications are free when available in the public sector, chemotherapy medications were unaffordable, costing government worker salary equivalents of 47-242 days, 233-869 days, and 22-196 days to treat early-stage breast cancer, CRC, and head and neck cancer, respectively. On average across the population, $36 US dollars (USD) (95% CI, $50 USD to $134 USD, 9%-25% of medication cost) was spent on poor-quality medicines for treatment of breast cancer, $32 USD (95% CI, $6 USD to $214 USD, 0.5%-17%) for CRC, and $15 USD (95% CI, $4 USD to $49 USD, 2%-21%) for head and neck cancer. Price of the medication, public/private source, and medicine registration status were poor predictors of medicine quality.
conclusionWe found that medicines for cancer treatment are unaffordable without government subsidies. Moreover, poor-quality chemotherapy medicines are hard to detect without chemical testing. Government policies and supply chain practice changes are needed to improve the availability, affordability, and quality of chemotherapy medications in sub-Saharan Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.